IL193319A - Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases - Google Patents
Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseasesInfo
- Publication number
- IL193319A IL193319A IL193319A IL19331908A IL193319A IL 193319 A IL193319 A IL 193319A IL 193319 A IL193319 A IL 193319A IL 19331908 A IL19331908 A IL 19331908A IL 193319 A IL193319 A IL 193319A
- Authority
- IL
- Israel
- Prior art keywords
- use according
- aat
- medicament
- administration
- pulmonary disease
- Prior art date
Links
Claims (24)
1. Use of a therapeutically effective amount of naturally occurring, purified alpha- 1 antitrypsin (AAT) for the preparation of a medicament for treating an exacerbation of a pulmonary disease or disorder at the time of the exacerbation episode, wherein the medicament is in a form of a ready-to-use, aqueous sterile solution and the purified AAT is at least 90% pure and at least 90% of the AAT is in its active form.
2. The use according to claim 1 , wherein the medicament is formulated for administration by inhalation.
3. The use according to claim 1 , wherein the pulmonary disease or disorder is selected from the group consisting of emphysema; chronic obstructive pulmonary disease (COPD); bronchiectasis; parenchymatic and fibrotic lung diseases or disorders: cystic fibrosis, interstitial pulmonary fibrosis and sarcoidosis; tuberculosis and lung diseases and disorders secondary to HIV.
4. The use according to claim 1 , wherein the pulmonary disease or disorder is selected from the group consisting of COPD and emphysema.
5. The use according to claim 1 , wherein the pulmonary disease or disorder is associated with AAT-deficiency.
6. The use according to claim 5, wherein the pulmonary disease is congenital emphysema.
7. The use according to claim 1 wherein the AAT is purified from an unpurified mixture of proteins by a process comprising of chromatography on a plurality of ion exchange resins.
8. The use according to claim 7, wherein the AAT is purified from an unpurified mixture of proteins by a process comprising of chromatography on at least two anion exchange resins and at least one cation exchange resin.
9. The use according to claim 1, wherein the medicament is devoid of a stabilizer.
10. The use according to claim 2, wherein the medicament is for administration in the form of an aerosol spray.
11. 1 1. The use according to claim 10, wherein the aerosol is produced by a nebulizer.
12. The use according to claim 10, wherein the medicament is devoid of a stabilizer.
13. The use according to claim 1 1, wherein the activity of the AAT within the aerosolized medicament remains at above 90% of said AAT activity before aerosolization.
14. The use according to claim 1 1 wherein the mass radian diameter of the aerosol droplets is less than about 5 μηι.
15. The use according to claim 1 1, wherein the AAT concentration in the medicament to be aerosolized is 0.5% to 10% w/v.
16. The use according to claim 10 wherein at least 50% of the loaded nominal dose of AAT is administered.
17. The use according to claim 10 wherein at least 60% of the loaded nominal dose of AAT is administered.
18. The use according to claim 10 wherein at least 70% of the loaded nominal dose of AAT is administered.
19. The method according to claim 2, wherein the medicament is formulated for administration at least once a week.
20. The use according to claim 2, wherein the medicament is formulated for administration at least twice a week.
21. The use according to claim 2, wherein the medicament is formulated for administration at least once a day.
22. The use according to claim 2, wherein the medicament is for administration in combination with at least one additional therapy.
23. The use according to claim 22, wherein the additional therapy is selected from the group consisting of an antibiotic therapy, administration of bronchodilators and antiinflammatory therapy other than AAT therapy.
24. The use according to claim 22, wherein the additional therapy is intravenous administration of AAT. For Hedva Schickler Patent Attorney Webb & Co.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL193319A IL193319A (en) | 2006-02-09 | 2008-08-07 | Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77146506P | 2006-02-09 | 2006-02-09 | |
| US77365406P | 2006-02-16 | 2006-02-16 | |
| PCT/IL2007/000181 WO2007091266A2 (en) | 2006-02-09 | 2007-02-08 | Alpha-i antitrypsin for treating exacerbation episodes of pulmonary diseases |
| IL193319A IL193319A (en) | 2006-02-09 | 2008-08-07 | Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL193319A0 IL193319A0 (en) | 2011-08-01 |
| IL193319A true IL193319A (en) | 2012-03-29 |
Family
ID=44671833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL193319A IL193319A (en) | 2006-02-09 | 2008-08-07 | Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases |
Country Status (1)
| Country | Link |
|---|---|
| IL (1) | IL193319A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3585423A4 (en) * | 2017-02-21 | 2020-12-23 | Kamada Ltd. | Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases |
-
2008
- 2008-08-07 IL IL193319A patent/IL193319A/en active IP Right Grant
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3585423A4 (en) * | 2017-02-21 | 2020-12-23 | Kamada Ltd. | Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases |
| US10960062B2 (en) | 2017-02-21 | 2021-03-30 | Kamada Ltd. | Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases |
| IL268752B1 (en) * | 2017-02-21 | 2023-09-01 | Kamada Ltd | Methods and uses of alpha 1-antitrypsin for early intervention in pulmonary diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| IL193319A0 (en) | 2011-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008135580A (en) | ALPHA-1-ANTITRIPSIN FOR TREATMENT OF EPISODES OF INFLAMMATION OF LUNG DISEASES | |
| Newman | Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases | |
| Pai et al. | Efficacy and safety of aerosolized tobramycin in cystic fibrosis | |
| JP2008536546A5 (en) | ||
| JP2017505348A (en) | Mast cell stabilizer for the treatment of lung diseases | |
| CZ20033580A3 (en) | Aerosol preparation | |
| KR20010099865A (en) | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs | |
| AU2012306076A1 (en) | Treating cough and tussive attacks | |
| WO2006060027A3 (en) | A method for improvement of tolerance for therapeutically effective agents delivered by inhalation | |
| US20070185067A1 (en) | Ciclesonide and glycopyrronium combination | |
| US20100202979A1 (en) | Compositions and methods for treatment of pulmonary diseases and conditions | |
| JP2008502699A5 (en) | ||
| IL193319A (en) | Alpha-1 antitrypsin for treating exacerbation episodes of pulmonary diseases | |
| CN104784218A (en) | Probiotics powder for respiratory tract | |
| KR20140025534A (en) | Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia(vap) and ventilator associated tracheal(vat) bronchitis | |
| JP2016534122A (en) | Aminoglycoside and fosfomycin combination formulation with improved chemical properties | |
| IL275328B1 (en) | Methods of inducing immune tolerance and reducing anti-drug antibody response | |
| KR20130140672A (en) | Carbonate derivatives for the treatment of cough | |
| US20040019022A1 (en) | Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction, damage and injury in mammals | |
| Tabachnik et al. | Clinical application of aerosols in pediatrics | |
| Simon et al. | Drug treatment of COPD: controversies about agents and how to deliver them | |
| US20210338718A1 (en) | Methods for preventing and treating pulmonary inflammation and fibrosis | |
| Bernstein et al. | Therapeutic uses of lung aerosol | |
| Kaajan | Chronic obstructive pulmonary disease and asthma: General and medical management with special attention to exacerbations | |
| Norek | Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |